Skip to content

CDR

Retail/PBM Rx model still holds promise

Walgreens’ decision to sell its pharmacy benefits management business to Catalyst Health Solutions for $525 million is sure to intensify the debate about whether drug chains are well served by owning and operating such entities. For Walgreens, at least, the answer is clearly no.

Qualitest approved for toresmide tablets

Qualitest Pharmaceuticals has received clearance for toresmide tablets, a diuretic medication. The Endo Pharmaceuticals subsidiary said Thursday that the Food and Drug Administration has approved toresmide tablets in 5 mg, 10 mg, 20 mg and 100 mg strengths.

Wrigley offers personalized Extra gum packs

Wm. Wrigley Jr. Co. is enabling chewers of its Extra sugar-free gum to create and buy personalized packs featuring their photos and designs via its first-ever custom-packaging offer, dubbed MyExtra. Under the program unveiled Monday, consumers can visit www.MyExtraGum.

States sign on to NABP Rx monitoring system

The prescription monitoring programs (PMPs) of North Dakota, Ohio and Virginia have agreed to participate in the PMP Interconnect system to fight drug diversion and abuse, according to the National Association of Boards of Pharmacy (NABP).

Walgreens to buy drugstore.com for $409M

Walgreens to buy drugstore.com for $409M

In a move to expand its e-commerce business and expertise, Walgreen Co. plans to acquire drugstore.com in a deal valued at $409 million. Walgreens said Thursday that under the agreement, it will acquire the drugstore.

Earnings surge in 2Q at Walgreens

Earnings surge in 2Q at Walgreens

Walgreen Co. saw earnings rise by double digits in its fiscal 2011 second quarter and first half, lifted by robust revenue and same-store sales growth. Walgreens said Tuesday that net earnings for the second quarter ended Feb. 28 came in at $739 million, or 80 cents per diluted share, up 10.4% from

Covidien CEO to retire; successor named

Richard Meelia is slated to retire as president and chief executive officer of Covidien this summer. The pharmaceutical and health care products company said plans call for Meelia to retire on July 1 and then serve as nonexecutive chairman during a transition period of up to one year.